Due to this and the possibility of increased risk of infection, drug-induced Lupus Erythematosus, and possible increased risk of cancer, many healthcare professionals avoid using anti-TNF-α therapies as treatment for SLE [13,14,15]. The gene discussed is TNF; the disease is systemic lupus erythematosus.